Filing Flows › Insight Molecular Diagnostics (IMDX) › Q1 2026
Insight Molecular Diagnostics (IMDX) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 13, 2026
Insight Molecular Diagnostics (IMDX) reported revenue of $32K for the first quarter 2026 (Q1 2026), -99% from a year earlier and -97% from the quarter before.
Insight Molecular Diagnostics, Q1 2026: revenue $32K (-98% year over year), net loss $4.3M, operating cash flow −$7.6M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $32K | -97% | -99% |
| Operating profit | −$4.4M | — | — |
| Net earnings | −$4.3M | — | — |
| Operating cash flow | −$7.6M | — | — |
What changed
Revenue was $32K in Q1 2026, down 99% year over year and down 97% from the previous quarter.
Gross margin was 46.9%, down 15.1 points from Q1 2025. Operating costs exceeded revenue by $4.4M, an operating margin of -13790.6%. Operating expenses fell 45% while revenue fell 99%. The quarter ended with a net loss of $4.3M, narrower than the previous quarter's $23.0M loss.
Operating cash flow was −$7.6M. Non-cash charges added back $631K of depreciation and amortization and $615K of share-based compensation. Working capital and other items used $4.6M. Capital expenditures of $613K exceeded it, leaving free cash flow of −$8.3M.
Questions
What was Insight Molecular Diagnostics' revenue in the first quarter 2026?
Insight Molecular Diagnostics (IMDX) reported revenue of $32K for the first quarter 2026 (Q1 2026), -99% from a year earlier and -97% from the quarter before.